



(51) International Patent Classification:

C07D 231/54 (2006.01) *C07D 405/04* (2006.01)
A61K 31/416 (2006.01) *C07D 405/12* (2006.01)
C07D 401/04 (2006.01) *C07D 491/113* (2006.01)
C07D 403/04 (2006.01) *A61P 29/00* (2006.01)

(21) International Application Number:

PCT/US2013/055267

(22) International Filing Date:

16 August 2013 (16.08.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/683,775 16 August 2012 (16.08.2012) US

(71) Applicant: **JANSSEN PHARMACEUTICA NV** [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).

(72) Inventor; and

(71) Applicant: **WINTERS, Michael P.** [US/US]; 17 Hunters Hill Drive, Morgantown, Pennsylvania 19543 (US).

(72) Inventors: **SUI, Zhihua**; 36 Birchview Drive, Piscataway, New Jersey 08854 (US). **FLORES, Christopher**; 107 Veronica Lane, Lansdale, Pennsylvania 19446 (US).

(74) Agents: **JOHNSON, Philip S.** et al.; Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.



(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: CYCLOPENTYLPYRAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS

(57) Abstract: Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) as follows: wherein R¹, R², R³, Q, and G are defined herein.

Figure 1: Rat CFA Radiant Heat Model of Inflammatory Pain
Cpd 71
(30 mg/kg, p.o.)



**Declarations under Rule 4.17:**

— as to the identity of the inventor (Rule 4.17(i))

— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

Published:

— with international search report (Art. 21(3))